Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro - Concepedia

Concepedia

Publication | Open Access

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

DOI Full Paper Access

10

Citations

33

References

2015

Year

Liancheng Zhu, Salvatore Lopez, Stefania Bellone, Jonathan Black, Emiliano Cocco, Tiffany Zigras, Federica Predolini, Elena Bonazzoli, Beatrice Bussi, Zachary Stuhmer,

References

	Year	Citations

Page 1